ResMed (RMD) Reports In-Line Q4 EPS
Tweet
Share
E-mail
Get Alerts RMD Hot Sheet
Price: $196.29 +2.63%
EPS Growth %: +13.3%
Financial Fact:
Total operating expenses: 175.04M
Today's EPS Names:
DTGI, CRMT, MAYS, More
EPS Growth %: +13.3%
Financial Fact:
Total operating expenses: 175.04M
Today's EPS Names:
DTGI, CRMT, MAYS, More
Join SI Premium – FREE
ResMed (NYSE: RMD) reported Q4 EPS of $0.74, in-line with the analyst estimate of $0.74. Revenue for the quarter came in at $518.6 million versus the consensus estimate of $513.97 million.
For earnings history and earnings-related data on ResMed (RMD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JPMorgan raises S&P 500 target to 7,800, says earnings revision ’unprecedented’
- GTA VI to catalyze a multi-year improvement in earnings power for TTWO, BTIG says
- NXP Semiconductors names Mike Lucarelli as new investor relations head
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
